Cetrorelix vs Ganirelix
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Cetrotide, Cetrorelix acetate
Cetrorelix is a GnRH antagonist: a modified 10-amino-acid version of the brain's gonadotropin-releasing hormone that blocks its receptor instead of activating it. Sold as Cetrotide and FDA-approved since August 2000, its job in IVF is narrow and important: it stops the body's own LH surge from releasing eggs too early while the ovaries are being stimulated. It is a well-established fertility drug with decades of use, and it is not a tool for anything else people sometimes imagine it for.
Also: Ganirelix acetate, Orgalutran
Ganirelix is a GnRH antagonist used in IVF to stop the body from ovulating too early while the ovaries are being stimulated. The FDA approved it in July 1999 (originally from Organon, now also sold as generics such as Fyremadel), and it comes as a ready-to-use 250 mcg prefilled syringe. It does the same job as cetrorelix, with a slightly longer half-life. It is a boring, reliable fertility drug, and that is a compliment.
Key Comparison Insights
- Both Cetrorelix and Ganirelix are FDA approved medications.
- Both peptides belong to the Hormonal category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Cetrorelix | Ganirelix |
|---|---|---|
| Category | Hormonal | Hormonal |
| FDA Status | FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | The pituitary releases LH and FSH in response to GnRH. Cetrorelix competes with natural GnRH for the pituitary receptor and shuts that signal down within hours (about 2 hours for the 0.25 mg dose), with a stronger effect on LH than FSH. Unlike GnRH agonists such as leuprolide, there is no initial flare of hormone release, so it can be started mid-cycle rather than weeks ahead. The effect is reversible once dosing stops. In IVF this prevents a premature LH surge, which would otherwise trigger ovulation before the eggs can be retrieved. Because the same signal drives testosterone in men, a GnRH antagonist suppresses testosterone, which is the opposite of what anyone seeking an anabolic effect wants. | Ganirelix is a modified version of GnRH with six amino-acid swaps that turn it into a receptor blocker. It competitively blocks GnRH receptors on the pituitary, causing a fast, reversible drop in LH (and to a lesser extent FSH) without the initial hormone flare that GnRH agonists cause. That lets clinics start it mid-cycle, usually around day 6 of FSH injections, to prevent a premature LH surge. Pituitary LH and FSH fully recover within 48 hours of stopping. Its half-life is about 13 hours after one dose and 16 hours with daily use, so once-daily injections keep the block steady. In men the same block lowers testosterone. |
| Common Dosing | 0.25 mg once daily during IVF stimulation (labeled dose) Once daily | 250 mcg once daily during IVF stimulation (labeled dose) Once daily |
| Administration | Subcutaneous injection in the lower abdomen; can be self-administered after instruction, first dose under medical supervision | Subcutaneous injection from a prefilled syringe |
| Typical Duration | A few days per IVF cycle (median 5 days in trials, range 1-15) | A few days per IVF cycle (mean 5.4 days in trials, range 2-14) |
| Best Time to Take | Same time each day, starting stimulation day 5 or 6 | Same time each day, usually starting around day 6 of FSH |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The FDA approval rests on five trials covering 732 women. In phase 3, the multiple-dose 0.25 mg regimen and a single 3 mg dose regimen each prevented premature LH surges in nearly everyone (LH surge rates of 0-1.9%), with clinical pregnancy rates around 20-23% per attempt, typical for IVF at that time. Larger phase 3b experience (Olivennes and colleagues, 2003, over 1,600 women) found the two regimens similar, with severe OHSS in under 1% of cycles. The best overall evidence on antagonists as a class is the 2016 Cochrane review (73 trials, over 12,000 women): compared with the older long GnRH-agonist protocol, antagonists gave similar live birth rates but substantially less ovarian hyperstimulation syndrome. That is why antagonist protocols became standard in many clinics. Outside IVF, cetrorelix was tested for benign prostatic hyperplasia, but two phase 3 trials in 2009 found it no better than placebo, and that program was dropped. | Two well-controlled trials supported approval. A double-blind dose-finding study in 332 women tested 62.5 to 2,000 mcg and found 250 mcg gave the best pregnancy and implantation rates (higher doses over-suppressed estrogen and lowered pregnancy rates). An open-label trial of 463 women on 250 mcg daily saw premature LH surges in under 1%, with an ongoing pregnancy rate of about 20% per attempt. The North American phase 3 trial (Fluker and colleagues, 2001, 313 women) compared ganirelix with a long leuprolide protocol: slightly fewer eggs (11.6 vs 14.1) and numerically lower pregnancy rates, but shorter treatment, fewer injections and fewer injection site reactions. The 2016 Cochrane review of 73 trials across GnRH antagonists found live birth rates similar to the long agonist protocol with clearly less ovarian hyperstimulation syndrome. One honest note: the label's adverse event table lists fetal death at 3.7%, which reflects early pregnancy loss in IVF patients generally, not a proven drug effect, and a follow-up of over 1,000 newborns found congenital anomaly rates comparable to agonist-treated cycles. |
Frequently Asked Questions: Cetrorelix vs Ganirelix
What is the difference between Cetrorelix and Ganirelix?
Cetrorelix is a hormonal peptide that cetrorelix is a gnrh antagonist: a modified 10-amino-acid version of the brain's gonadotropin-releasing hormone that blocks its receptor instead of activating it. sold as cetrotide and fda-approved since august 2000, its job in ivf is narrow and important: it stops the body's own lh surge from releasing eggs too early while the ovaries are being stimulated. it is a well-established fertility drug with decades of use, and it is not a tool for anything else people sometimes imagine it for. Ganirelix is a hormonal peptide that ganirelix is a gnrh antagonist used in ivf to stop the body from ovulating too early while the ovaries are being stimulated. the fda approved it in july 1999 (originally from organon, now also sold as generics such as fyremadel), and it comes as a ready-to-use 250 mcg prefilled syringe. it does the same job as cetrorelix, with a slightly longer half-life. it is a boring, reliable fertility drug, and that is a compliment. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Cetrorelix or Ganirelix?
Neither is universally "better" - the choice depends on your specific goals. Cetrorelix is typically used for hormonal purposes, while Ganirelix is used for hormonal. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Cetrorelix and Ganirelix be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Cetrorelix and Ganirelix together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.